BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 10903347)

  • 1. A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats.
    Visentin L; Dodds RA; Valente M; Misiano P; Bradbeer JN; Oneta S; Liang X; Gowen M; Farina C
    J Clin Invest; 2000 Jul; 106(2):309-18. PubMed ID: 10903347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (2Z,4E)-5-(5,6-dichloro-2-indolyl)-2-methoxy-N-(1,2,2,6,6- pentamethylpiperidin-4-yl)-2,4-pentadienamide, a novel, potent and selective inhibitor of the osteoclast V-ATPase.
    Nadler G; Morvan M; Delimoge I; Belfiore P; Zocchetti A; James I; Zembryki D; Lee-Rycakzewski E; Parini C; Consolandi E; Gagliardi S; Farina C
    Bioorg Med Chem Lett; 1998 Dec; 8(24):3621-6. PubMed ID: 9934482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition of osteoclast vacuolar H(+)-ATPase.
    Farina C; Gagliardi S
    Curr Pharm Des; 2002; 8(23):2033-48. PubMed ID: 12171517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.
    Lark MW; Stroup GB; James IE; Dodds RA; Hwang SM; Blake SM; Lechowska BA; Hoffman SJ; Smith BR; Kapadia R; Liang X; Erhard K; Ru Y; Dong X; Marquis RW; Veber D; Gowen M
    Bone; 2002 May; 30(5):746-53. PubMed ID: 11996914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application.
    Niikura K; Takeshita N; Takano M
    J Bone Miner Res; 2005 Sep; 20(9):1579-88. PubMed ID: 16059630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-(5,6-Dichloro-2-indolyl)-2-methoxy-2,4-pentadienamides: novel and selective inhibitors of the vacuolar H+-ATPase of osteoclasts with bone antiresorptive activity.
    Gagliardi S; Nadler G; Consolandi E; Parini C; Morvan M; Legave MN; Belfiore P; Zocchetti A; Clarke GD; James I; Nambi P; Gowen M; Farina C
    J Med Chem; 1998 May; 41(10):1568-73. PubMed ID: 9572882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel bone antiresorptive agents that selectively inhibit the osteoclast V-H+-ATPase.
    Farina C; Gagliardi S; Nadler G; Morvan M; Parini C; Belfiore P; Visentin L; Gowen M
    Farmaco; 2001; 56(1-2):113-6. PubMed ID: 11347950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of an inhibitor of cathepsin L on bone resorption in thyroparathyroidectomized and ovariectomized rats.
    Millest AJ; Breen SA; Loveday BE; Clarkson PN; Simpson CA; Waterton JC; Johnstone D
    Bone; 1997 May; 20(5):465-71. PubMed ID: 9145244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FR177995, a novel vacuolar ATPase inhibitor, exerts not only an inhibitory effect on bone destruction but also anti-immunoinflammatory effects in adjuvant-induced arthritic rats.
    Niikura K; Nakajima S; Takano M; Yamazaki H
    Bone; 2007 Apr; 40(4):888-94. PubMed ID: 17157574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform.
    Nyman JK; Väänänen HK
    Calcif Tissue Int; 2010 Sep; 87(3):273-83. PubMed ID: 20596699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacological assessment of the mammalian osteoclast vacuolar H(+)-ATPase.
    Hall TJ; Schaueblin M
    Bone Miner; 1994 Nov; 27(2):159-66. PubMed ID: 7711523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
    David P; Nguyen H; Barbier A; Baron R
    J Bone Miner Res; 1996 Oct; 11(10):1498-507. PubMed ID: 8889850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [3H]Bafilomycin as a probe for the transmembrane proton channel of the osteoclast vacuolar H(+)-ATPase.
    Mattsson JP; Keeling DJ
    Biochim Biophys Acta; 1996 Apr; 1280(1):98-106. PubMed ID: 8634321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis.
    Lark MW; Stroup GB; Hwang SM; James IE; Rieman DJ; Drake FH; Bradbeer JN; Mathur A; Erhard KF; Newlander KA; Ross ST; Salyers KL; Smith BR; Miller WH; Huffman WF; Gowen M
    J Pharmacol Exp Ther; 1999 Nov; 291(2):612-7. PubMed ID: 10525079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SB 242784, a selective inhibitor of the osteoclastic V-H+ATPase, inhibits arterial calcification in the rat.
    Price PA; June HH; Buckley JR; Williamson MK
    Circ Res; 2002 Sep; 91(6):547-52. PubMed ID: 12242274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the bisphosphonate tiludronate on bone resorption, calcium balance, and bone mineral density.
    Ammann P; Rizzoli R; Caverzasio J; Shigematsu T; Slosman D; Bonjour JP
    J Bone Miner Res; 1993 Dec; 8(12):1491-8. PubMed ID: 8304051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.
    Kim MK; Kim HD; Park JH; Lim JI; Yang JS; Kwak WY; Sung SY; Kim HJ; Kim SH; Lee CH; Shim JY; Bae MH; Shin YA; Huh Y; Han TD; Chong W; Choi H; Ahn BN; Yang SO; Son MH
    J Pharmacol Exp Ther; 2006 Aug; 318(2):555-62. PubMed ID: 16699068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption.
    Qin A; Cheng TS; Pavlos NJ; Lin Z; Dai KR; Zheng MH
    Int J Biochem Cell Biol; 2012 Sep; 44(9):1422-35. PubMed ID: 22652318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption.
    Sørensen MG; Henriksen K; Neutzsky-Wulff AV; Dziegiel MH; Karsdal MA
    J Bone Miner Res; 2007 Oct; 22(10):1640-8. PubMed ID: 17576165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase.
    Niikura K; Takano M; Sawada M
    Br J Pharmacol; 2004 Jun; 142(3):558-66. PubMed ID: 15148249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.